SRF is Hiring
We are currently seeking to hire two new Research Assistants, to join our MitoSENS and LysoSENS teams on a full-time basis. Could you be one of them? Check out the application forms linked via our jobs page to learn more!
Rejuvenating the Mitochondria
As part of Google's Giving Week, MitoSENS project leader Dr. Matthew O'Connor gave a Tech Talk on December 9th introducing SRF and our "damage repair" approach to fighting aging - followed by an update on our progress in repairing defective mitochondria.
2017 Summer Scholars Apply!
The application for the 2017 Summer Scholars Program is now available. Submissions will be accepted until 12 pm PST Feb 6, 2017. Undergraduate students looking for a 2017 summer research experience are encouraged to apply.
Aging Runs In The Blood
Surgically connecting young and old mice reverses some aspects of aging, but isn't practical for humans! Fortunately for us, new SRF-funded work shows that transfusions of young blood produce many of the same benefits - paving the way towards human trials.
January 18th Newsletter
Check out all the latest news from SENS Research Foundation in our January newsletter. You might also like to check out the archive of past messages, or subscribe to our mailing list to make sure you don't miss out on future updates!
Faces of Cancer
During our Control ALT, Delete Cancer fundraiser, we invited donors to send us a photo of a friend or loved one whose life has been affected by, or lost to, cancer. We've assembled those images into our Faces of Cancer wall.
More Progress in Senolytics
Deleting senescent cells from mice delays many age-related diseases. A recent paper from the Unity Biotechnology team, who aim to start human trials in 12-18 months, now identifies atherosclerosis as another deadly condition which may be prevented by senolytic drugs.
Our 115-Year Shelf Life?
A recent demographic analysis in Nature by Vijg et al. has attracted global attention after concluding that there is a "natural limit" of around 115 years to human lifespans - but has also been criticised for undue pessimism regarding future medical advances.
Funding a Cure for Aging
Project|21's first patron, German internet entrepeneur Michael Greve, has formally announced a list of the research efforts that will be supported over the next year by the initial $1m tranche of his donation - as well as the startup companies receiving seed funds.
New MitoSENS Publication
Our newest paper has just been published in Nucleic Acids Research, demonstrating the simultaneous rescue of two mitochondrial mutations by new nuclear genes. We're grateful to everyone who donated to our 2015 crowdfunding campaign, which paid for this study!
SENS Research Foundation has commissioned a series of 8 animations, narrated by actor Edward James Olmos, to explain the concept of SENS and some of the therapies that we're developing to end age-related disease for good.
Michael Greve, the first donor to our Project|21 campaign, gave a presentation at RB2016 discussing how his life led to a passionate interest in the long-term maintenance of human health - and ultimately his decision to commit $10 million to our work.
Project|21 is a new initiative created by SENS Research Foundation to advance rejuvenation biotechnology to human clinical trials by 2021, through three complementary programs: the Bridge Fund, the Center of Excellence, and the Alliance Program.
Want to support SRF for free? When you use our Amazon Smile link to purchase goods, Amazon automatically donates part of your payment to us - and it won't cost you an extra cent!
Michael Greve Commits $10m
Internet entrepreneur Michael Greve is the first donor to our new Project|21 campaign, with a gift of $5 million towards SENS research programs. Michael has also pledged a further $5 million in seed funding for startups in the field of rejuvenation biotechnology.
Why Control ALT?
Veteran longevity science blogger Reason highlights the significance of SRF's new Control ALT, Delete Cancer campaign within the broader context of cancer research, and interviews lead researcher Dr. Haroldo Silva.
Entrepreneur and biohacker Dave Asprey recently interviewed our Chief Science Officer, Dr. Aubrey de Grey, for the health podcast Bulletproof Radio. Their in-depth conversation covers a broad range of topics related to our current work and future plans.
Ending Aging Audiobook
Our general introduction to SENS research, Ending Aging, is now available in audiobook format. All profits will go to SENS Research Foundation. If Ending Aging is your first purchase as a new Audible member, we also get a $50 "bounty" - so please consider signing up!